Bagsværd, Denmark, Nov. 25, 2025 — Novo Nordisk has announced positive Phase 2 clinical trial results for amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, demonstrating statistically significant weight loss of up to 14.5% and HbA1c reductions of up to –1.8% in adults with type 2 diabetes inadequately controlled on metformin, marking a major advancement in the company’s expanding metabolic-disease portfolio and setting the stage for a Phase 3 programme in 2026.
Science Significance
The Phase 2 results underscore the scientific strength of amycretin’s dual-action design, leveraging the complementary biology of GLP-1 and amylin pathways to deliver substantial metabolic improvements. Across subcutaneous doses ranging from 0.4 mg to 40 mg weekly, amycretin achieved up to –14.5% weight loss, while oral doses up to 50 mg daily achieved –10.1% weight loss, both far exceeding placebo responses. In addition, up to 89.1% of participants achieved HbA1c levels below 7%, signaling a highly potent glucose-lowering profile. Importantly, no plateau in weight loss was observed at week 36, suggesting continued efficacy beyond the trial duration. Safety findings remained consistent with incretin and amylin-based mechanisms, with mostly mild gastrointestinal events, reinforcing the molecule’s strong potential as a next-generation metabolic therapy.
Regulatory Significance
These findings deliver critical momentum for Novo Nordisk’s regulatory pathway, validating amycretin’s dose-response relationship, confirming primary and secondary endpoints, and demonstrating a well-tolerated safety profile, all essential criteria for advancement toward Phase 3 studies in 2026. Regulatory agencies increasingly expect metabolic-disease therapies to show clinically meaningful HbA1c reductions and weight-loss outcomes, both of which amycretin achieved at clinically superior levels. The robust double-blind, placebo-controlled, multi-centre study design strengthens the regulatory package, while the availability of both oral and injectable formulations enhances amycretin’s profile as a potentially versatile, patient-centric therapy.
Business Significance
Advertisement
For Novo Nordisk, amycretin represents a major strategic asset in an increasingly competitive metabolic-therapeutics landscape. Following the commercial success of GLP-1 agents globally, amycretin’s promising efficacy supports the company’s ambition to sustain its leadership in diabetes and obesity markets, among the fastest-growing segments in global biopharma. With nine active treatment arms and strong dose-dependent outcomes, the candidate strengthens Novo Nordisk’s future revenue prospects and reinforces its innovation pipeline at a time when demand for incretin-based therapies continues to accelerate. The positive data also signals long-term market confidence, with amycretin positioned as a potential best-in-class therapy once commercialized.
Patients’ Significance
For people living with type 2 diabetes, these results offer meaningful hope. Achieving HbA1c below 7% in up to 89.1% of participants and delivering double-digit weight reductions presents a substantial improvement over current standards of care, particularly for patients inadequately controlled on metformin or SGLT2 inhibitors. Amycretin’s flexible dosing — once-weekly injection or once-daily oral administration — provides patient-friendly options that may improve adherence and long-term metabolic control. As diabetes and obesity continue to rise globally, a therapy that addresses both glycemic control and weight management could significantly impact patient outcomes and quality of life.
Policy Significance
The strong Phase 2 results arrive at a time when global health systems face escalating burdens from diabetes, obesity, and cardiometabolic disease. Therapies that lower long-term complications can reduce healthcare costs, improve workforce productivity, and support public-health initiatives focused on preventing chronic disease progression. Amycretin’s dual-pathway mechanism aligns with policy priorities to encourage innovative, high-impact treatments that can reduce hospitalizations and disease severity. As regulatory bodies push for more effective metabolic therapies, amycretin’s clinical performance positions it as a strong candidate for future inclusion in treatment guidelines and reimbursement frameworks, reinforcing its significance beyond clinical outcomes.
Novo Nordisk’s Phase 2 data for amycretin marks a major milestone in the development of next-generation metabolic therapeutics, demonstrating significant weight loss, meaningful HbA1c reductions, and a favorable safety profile. With Phase 3 trials planned for 2026, the company is poised to advance a therapy with the potential to reshape type 2 diabetes and obesity management. As global demand grows for more effective, safe, and patient-friendly metabolic treatments, amycretin stands out as a promising breakthrough with the scientific, regulatory, and clinical strength to transform patient care worldwide.
Source: Novo Nordisk press release
